A Phase 1 interventional study of MLN7243 in Advanced Malignant Solid Tumors, sponsored by Millennium Pharmaceuticals, Inc.. Terminated at 7 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-03-14.
Sponsored by Millennium Pharmaceuticals, Inc. (part of Takeda) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to evaluate safety and tolerability (establish maximum tolerated dose [MTD], inform the recommended phase 2 dose [RP2D], and identify the dose-limiting toxicities [DLTs]) of MLN7243.
This is a single arm Phase I study with multiple dosing cohorts as noted below:
Millennium Pharmaceuticals, Inc. is the lead sponsor of 178 studies on the registry; none are open to participants now.
Of its 74 completed or terminated interventional studies of FDA-regulated products, 73 (99%) have results posted.
First submitted after Millennium Pharmaceuticals, Inc. became part of Takeda.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Each participant must meet all of the following inclusion criteria to be enrolled in the study:
Female participants who are for at least 1 year before the screening visit, surgically sterile, or agree to practice 2 effective methods of , at the same time, from the time of signing the form through 4 months after the last dose of study drug, or agree to practice true abstinence.
Male participants who agree to practice effective barrier contraception during the entire study treatment period through 4 months after the last dose of study drug or agree to practice true abstinence.
Exclusion Criteria
Participants meeting any of the following exclusion criteria are not to be enrolled in the study:
For participants where tumor are required or requested:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MLN7243 1 milligram (mg), infusion, intravenously over 10-minutes, on Days 1, 4, 8, and 11 followed by 10 days of rest in a 21-day treatment cycle for a maximum of 12 months, or until symptomatic deterioration or disease progression (PD) or discontinuation of study for another reason, or until study is stopped.
Drug: MLN7243
MLN7243 2 mg, infusion, intravenously over 10-minutes, on Days 1, 4, 8, and 11 followed by 10 days of rest in a 21-day treatment cycle for a maximum of 12 months, or until symptomatic deterioration or PD, or discontinuation of study for another reason, or until study is stopped.
Drug: MLN7243
MLN7243 4 mg, infusion, intravenously over 10-minutes, on Days 1, 4, 8, and 11 followed by 10 days of rest in a 21-day treatment cycle for a maximum of 12 months, or until symptomatic deterioration or PD or discontinuation of study for another reason, or until study is stopped.
Drug: MLN7243
MLN7243 8 mg, infusion, intravenously over 10-minutes, on Days 1, 4, 8, and 11 followed by 10 days of rest in a 21-day treatment cycle for a maximum of 12 months, or until symptomatic deterioration or PD or discontinuation of study for another reason, or until study is stopped.
Drug: MLN7243
MLN7243 12 mg, infusion, intravenously over 10-minutes, on Days 1, 4, 8, and 11 followed by 10 days of rest in a 21-day treatment cycle for a maximum of 12 months, or until symptomatic deterioration or PD or discontinuation of study for another reason, or until study is stopped.
Drug: MLN7243
MLN7243 18 mg, infusion, intravenously over 10-minutes, on Days 1, 4, 8, and 11 followed by 10 days of rest in a 21-day treatment cycle for a maximum of 12 months, or until symptomatic deterioration or PD or discontinuation of study for another reason, or until study is stopped.
Drug: MLN7243
MLN7243 homozygous mutant 4 mg, infusion, intravenously over 10-minutes, on Days 1, 4, 8, and 11 followed by 10 days of rest in a 21-day treatment cycle for a maximum of 12 months, or until symptomatic deterioration or PD or discontinuation of study for another reason, or until study is stopped.
Drug: MLN7243
Dose escalation stage Schedule A: Intravenous infusion on Days 1, 4, 8, 11 for a 21-day treatment cycle. Schedule B: Intravenous infusion on Days 1, 8, 15 for a 28-day treatment cycle. Dose expansion stage: MLN7243 will be administered following schedule A (twice-weekly, 21-day dosing) and/or B (once-weekly, 28-day dosing).
Also known as: TAK-243
Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Time frame: Baseline up to 30 days after last dose of study drug (Cycle 10 Day 41)
Number of Participants With Laboratory Related TEAEs by System Organ Class (SOC)
Time frame: Baseline up to 30 days after last dose of study drug (Cycle 10 Day 41)
Number of Participants With Vital Sign Related TEAEs by Preferred Term (PT)
Time frame: Baseline up to 30 days after last dose of study drug (Cycle 10 Day 41)
Number of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities
Time frame: Cycle 1 Day 1 up to Cycle 1 Day 11
Number of Participants With Clinically Significant Echocardiogram Abnormalities
Time frame: Cycle 1 Day 2 up to 30 days after last dose of study drug (Cycle 10 Day 41)
Number of Participants With TEAEs Related to Tropinin I and T
Time frame: Baseline up to 30 days after last dose of study drug (Cycle 10 Day 41)
Ceoi: Plasma Concentration at the End of Infusion for TAK-243
Time frame: Cycle 1 Day 1 and 11: pre-infusion to end of infusion (up to 10 minutes)
AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-243
Time frame: Cycle 1 Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose; Cycle 1 Day 11 pre-dose and at multiple time points (up to 72 hours) post-dose
AUCτ: Area Under the Plasma Concentration-time Curve Over the Dosing Interval for TAK-243
Time frame: Cycle 1 Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose; Cycle 1 Day 11 pre-dose and at multiple time points (up to 72 hours) post-dose
AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-243
Time frame: Cycle 1 Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose; Cycle 1 Day 11 pre-dose and at multiple time points (up to 72 hours) post-dose
CL: Total Clearance After Intravenous Administration for TAK-243
Time frame: Cycle 1 Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose; Cycle 1 Day 11 pre-dose and at multiple time points (up to 72 hours) post-dose
Vss: Volume of Distribution at Steady State for TAK-243
Time frame: Cycle 1 Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose; Cycle 1 Day 11 pre-dose and at multiple time points (up to 72 hours) post-dose
Aet: Amount of TAK-243 Excreted Unchanged in Urine
Time frame: Cycle 1 Day 1; Cycle 1 Day 11
Fet: Percentage of TAK-243 Excreted Unchanged in Urine
Time frame: Cycle 1 Day 1; Cycle 1 Day 11
Terminal Phase Elimination Half-life (T1/2) for TAK-243
Time frame: Cycle 1 Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose; Cycle 1 Day 11 pre-dose and at multiple time points (up to 72 hours) post-dose
Change From Baseline in Immunohistochemistry (IHC) Biomarkers in Tumor Biopsies at Cycle 1 Day 12 (C1D12) as Assessed by Histological Score (H-score)
The pharmacodynamics IHC biomarkers included polyubiquitin marker and ubquityl (Ub)-histone H2B marker. H-score was a composite score that comprised of intensity and percentage of staining and was used for assessing the amount of protein or phospho-protein present in a biopsy sample. The composite score obtained by H-score is derived by summing the percentages of cell staining at each intensity multiplied by the weighted intensity of staining (0, 1+, 2+, 3+; where 3+ indicates the strongest staining, 2+ indicates medium staining, 1+ indicates weak staining, and 0 indicates no staining). The composite H-score ranges from 0 to 300, with a score of 0 representing the absence of any of the target protein and an H-score of 300 representing maximum staining and intensity of the target protein.
Time frame: Baseline and Cycle 1 Day 12
Change From Baseline in IHC Biomarkers in Tumor Biopsies at C1D12 as Assessed by Positive Index
The pharmacodynamics IHC biomarkers included polyubiquitin marker and Ub-histone H2B marker. Positive index was calculated by taking the number of positive cells over the total number of cells.
Time frame: Baseline and Cycle 1 Day 12
Percentage of Participants With Best Overall Response
Best overall response for participant is best observed post-baseline disease response as per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target and non target) must have reduction in short axis to less than (\<) 10 millimeter (mm). Partial Response (PR): at least 30 percent (%) decrease in sum of diameter of target lesions, taking as reference baseline sum of diameter. Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference smallest sum of diameter; PD: at least 20% increase in sum of diameter of target lesions, taking as reference, smallest sum on study (this includes baseline sum if that is smallest on study). In addition to relative increase of 20%, sum must also demonstrate an absolute increase of at least mm. The appearance of 1 or more new lesions is also considered progression.
Time frame: Baseline up to end of study (approximately 7 months)
Duration of Response
Duration of any response (CR or PR) was defined as the time (in both days and months) from the date of first documented response per the investigator response assessment to the date of first progressive disease after the first documented response or, if the participant discontinues treatment, the date of last disease assessment as per RECIST version 1.1. CR: Disappearance of all target lesions. Any pathological lymph nodes (whether target and non target) must have reduction in short axis to \<10 mm. PR: at least 30% decrease in sum of diameter of target lesions, taking as reference baseline sum of diameter.
Time frame: Baseline up to end of study (approximately 7 months)
Participants took part in the study at 7 investigative sites in the United States from 31 January 2014 to 09 November 2016.
| Milestone | Schedule A: TAK-243 1 mg | Schedule A: TAK-243 2 mg | Schedule A: TAK-243 4 mg | Schedule A: TAK-243 8 mg | Schedule A: TAK-243 12 mg | Schedule A: TAK-243 18 mg | Schedule A: TAK-243 Homozygous Mutant 4 mg |
|---|---|---|---|---|---|---|---|
| Started | 3 | 4 | 4 | 4 | 5 | 8 | 1 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 3 | 4 | 4 | 4 | 5 | 8 | 1 |
| Withdrew: Other | 0 | 0 | 1 | 0 | 0 | 2 | 0 |
| Withdrew: Progressive disease | 3 | 3 | 2 | 4 | 2 | 4 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 3 | 0 | 0 |
| Withdrew: Adverse event | 0 | 1 | 1 | 0 | 0 | 2 | 0 |
| participants | Schedule A: TAK-243 1 mg | Schedule A: TAK-243 2 mg | Schedule A: TAK-243 4 mg | Schedule A: TAK-243 8 mg | Schedule A: TAK-243 12 mg | Schedule A: TAK-243 18 mg | Schedule A: TAK-243 Homozygous Mutant 4 mg |
|---|---|---|---|---|---|---|---|
| TEAEs | 3 | 4 | 4 | 4 | 4 | 8 | 1 |
| SAEs | 1 | 1 | 2 | 2 | 1 | 4 | 0 |
| participants | Schedule A: TAK-243 1 mg | Schedule A: TAK-243 2 mg | Schedule A: TAK-243 4 mg | Schedule A: TAK-243 8 mg | Schedule A: TAK-243 12 mg | Schedule A: TAK-243 18 mg | Schedule A: TAK-243 Homozygous Mutant 4 mg |
|---|---|---|---|---|---|---|---|
| Metabolism and nutrition disorders | 1 | 1 | 1 | 3 | 1 | 4 | 1 |
| Blood and lymphatic system disorders | 1 | 1 | 1 | 2 | 0 | 4 | 0 |
| Investigations | 1 | 1 | 2 | 0 | 0 | 1 | 0 |
| participants | Schedule A: TAK-243 1 mg | Schedule A: TAK-243 2 mg | Schedule A: TAK-243 4 mg | Schedule A: TAK-243 8 mg | Schedule A: TAK-243 12 mg | Schedule A: TAK-243 18 mg | Schedule A: TAK-243 Homozygous Mutant 4 mg |
|---|---|---|---|---|---|---|---|
| Pyrexia | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Dyspnoea | 0 | 0 | 1 | 0 | 0 | 2 | 0 |
| Dyspnoea exertional | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Hypertension | 0 | 0 | 1 | 0 | 0 | 1 | 0 |
| participants | Schedule A: TAK-243 1 mg | Schedule A: TAK-243 2 mg | Schedule A: TAK-243 4 mg | Schedule A: TAK-243 8 mg | Schedule A: TAK-243 12 mg | Schedule A: TAK-243 18 mg | Schedule A: TAK-243 Homozygous Mutant 4 mg |
|---|---|---|---|---|---|---|---|
| Number of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| participants | Schedule A: TAK-243 1 mg | Schedule A: TAK-243 2 mg | Schedule A: TAK-243 4 mg | Schedule A: TAK-243 8 mg | Schedule A: TAK-243 12 mg | Schedule A: TAK-243 18 mg | Schedule A: TAK-243 Homozygous Mutant 4 mg |
|---|---|---|---|---|---|---|---|
| Number of Participants With Clinically Significant Echocardiogram Abnormalities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| participants | Schedule A: TAK-243 1 mg | Schedule A: TAK-243 2 mg | Schedule A: TAK-243 4 mg | Schedule A: TAK-243 8 mg | Schedule A: TAK-243 12 mg | Schedule A: TAK-243 18 mg | Schedule A: TAK-243 Homozygous Mutant 4 mg |
|---|---|---|---|---|---|---|---|
| Number of Participants With TEAEs Related to Tropinin I and T | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| nanogram per milliliter (ng/mL) | Schedule A: TAK-243 1 mg | Schedule A: TAK-243 2 mg | Schedule A: TAK-243 4 mg | Schedule A: TAK-243 8 mg | Schedule A: TAK-243 12 mg | Schedule A: TAK-243 18 mg | Schedule A: TAK-243 Homozygous Mutant 4 mg |
|---|---|---|---|---|---|---|---|
| Cycle 1 Day 1 | 78.658 ± 48.2212 | 100.758 ± 24.0669 | 473.075 ± 132.7667 | 921.804 ± 258.6109 | 1276.684 ± 804.4476 | 1775.470 ± 463.8601 | 391.000 ± NA |
| Cycle 1 Day 11 | 68.073 ± 35.2718 | 129.681 ± 52.4680 | 273.807 ± 179.4241 | 2299.438 ± 9027.7420 | 1271.199 ± 628.4555 | 2316.282 ± 7744.9842 | 265.000 ± NA |
| nanogram hours per milliliter (ng*hr/mL) | Schedule A: TAK-243 1 mg | Schedule A: TAK-243 2 mg | Schedule A: TAK-243 4 mg | Schedule A: TAK-243 8 mg | Schedule A: TAK-243 12 mg | Schedule A: TAK-243 18 mg | Schedule A: TAK-243 Homozygous Mutant 4 mg |
|---|---|---|---|---|---|---|---|
| Cycle 1 Day 1 | 32.853 ± 17.3894 | 52.845 ± 5.6656 | 312.714 ± 193.3829 | 368.071 ± 8.2218 | 867.427 ± 374.1800 | 922.068 ± 192.2359 | — |
| Cycle 1 Day 11 | 30.181 ± 12.8884 | 50.337 ± 8.9494 | 178.142 ± NA | — | — | — | 228.053 ± NA |
| ng*hr/mL | Schedule A: TAK-243 1 mg | Schedule A: TAK-243 2 mg | Schedule A: TAK-243 4 mg | Schedule A: TAK-243 8 mg | Schedule A: TAK-243 12 mg | Schedule A: TAK-243 18 mg | Schedule A: TAK-243 Homozygous Mutant 4 mg |
|---|---|---|---|---|---|---|---|
| Cycle 1 Day 1 | — | — | 535.581 ± NA | 377.812 ± NA | 1132.160 ± NA | 922.059 ± 192.1773 | — |
| Cycle 1 Day 11 | — | — | — | 506.693 ± NA | 663.176 ± 261.1957 | 771.491 ± 181.7875 | — |
| ng*hr/mL | Schedule A: TAK-243 1 mg | Schedule A: TAK-243 2 mg | Schedule A: TAK-243 4 mg | Schedule A: TAK-243 8 mg | Schedule A: TAK-243 12 mg | Schedule A: TAK-243 18 mg | Schedule A: TAK-243 Homozygous Mutant 4 mg |
|---|---|---|---|---|---|---|---|
| Cycle 1 Day 1 | — | — | 203.043 ± 10.0600 | 375.541 ± 11.2872 | 579.122 ± 201.1755 | 768.728 ± 174.9927 | — |
| Cycle 1 Day 11 | — | — | 179.726 ± NA | 509.785 ± NA | 752.152 ± NA | 864.533 ± 175.9351 | — |
| liter per hour (L/hr) | Schedule A: TAK-243 1 mg | Schedule A: TAK-243 2 mg | Schedule A: TAK-243 4 mg | Schedule A: TAK-243 8 mg | Schedule A: TAK-243 12 mg | Schedule A: TAK-243 18 mg | Schedule A: TAK-243 Homozygous Mutant 4 mg |
|---|---|---|---|---|---|---|---|
| Cycle 1 Day 1 | — | — | 19.724 ± 0.9773 | 21.312 ± 0.6406 | 22.749 ± 8.8967 | 24.379 ± 5.6587 | — |
| Cycle 1 Day 11 | — | — | 22.162 ± NA | 15.789 ± NA | 16.194 ± NA | 21.558 ± 4.8376 | — |
| liter | Schedule A: TAK-243 1 mg | Schedule A: TAK-243 2 mg | Schedule A: TAK-243 4 mg | Schedule A: TAK-243 8 mg | Schedule A: TAK-243 12 mg | Schedule A: TAK-243 18 mg | Schedule A: TAK-243 Homozygous Mutant 4 mg |
|---|---|---|---|---|---|---|---|
| Cycle 1 Day 1 | — | — | 29.806 ± 0.9494 | 33.957 ± 5.8273 | 37.596 ± 20.7520 | 63.744 ± 39.5945 | — |
| Cycle 1 Day 11 | — | — | 34.120 ± NA | 39.618 ± NA | 56.573 ± NA | 51.806 ± 18.8787 | — |
No measurements were reported for this outcome.
No measurements were reported for this outcome.
| hour | Schedule A: TAK-243 1 mg | Schedule A: TAK-243 2 mg | Schedule A: TAK-243 4 mg | Schedule A: TAK-243 8 mg | Schedule A: TAK-243 12 mg | Schedule A: TAK-243 18 mg | Schedule A: TAK-243 Homozygous Mutant 4 mg |
|---|---|---|---|---|---|---|---|
| Cycle 1 Day 1 | — | — | 7.001 ± 1.4372 | 9.377 ± 4.6442 | 5.765 ± 0.8607 | 8.296 ± 4.3573 | — |
| Cycle 1 Day 11 | — | — | 5.572 ± NA | 15.212 ± NA | 27.446 ± NA | 9.873 ± 6.3030 | — |
The pharmacodynamics IHC biomarkers included polyubiquitin marker and ubquityl (Ub)-histone H2B marker. H-score was a composite score that comprised of intensity and percentage of staining and was used for assessing the amount of protein or phospho-protein present in a biopsy sample. The composite score obtained by H-score is derived by summing the percentages of cell staining at each intensity multiplied by the weighted intensity of staining (0, 1+, 2+, 3+; where 3+ indicates the strongest staining, 2+ indicates medium staining, 1+ indicates weak staining, and 0 indicates no staining). The composite H-score ranges from 0 to 300, with a score of 0 representing the absence of any of the target protein and an H-score of 300 representing maximum staining and intensity of the target protein.
| score on a scale | Schedule A: TAK-243 1 mg | Schedule A: TAK-243 2 mg | Schedule A: TAK-243 4 mg | Schedule A: TAK-243 8 mg | Schedule A: TAK-243 12 mg | Schedule A: TAK-243 18 mg | Schedule A: TAK-243 Homozygous Mutant 4 mg |
|---|---|---|---|---|---|---|---|
| Baseline: Polyubiquitin H-score | 286.00 ± NA | 297.80 ± NA | 282.00 ± NA | — | — | — | — |
| Change at C1D12: Polyubiquitin H-score | -3.60 ± NA | -2.00 ± NA | 4.20 ± NA | — | — | — | — |
| Baseline: Ub-histone H2B H-score | 269.750 ± NA | 291.000 ± NA | 290.750 ± NA | — | — | — | — |
| Change at C1D12: Ub-histone H2B H-score | 13.250 ± NA | 3.250 ± NA | 2.000 ± NA | — | — | — | — |
The pharmacodynamics IHC biomarkers included polyubiquitin marker and Ub-histone H2B marker. Positive index was calculated by taking the number of positive cells over the total number of cells.
| percentage of cell | Schedule A: TAK-243 1 mg | Schedule A: TAK-243 2 mg | Schedule A: TAK-243 4 mg | Schedule A: TAK-243 8 mg | Schedule A: TAK-243 12 mg | Schedule A: TAK-243 18 mg | Schedule A: TAK-243 Homozygous Mutant 4 mg |
|---|---|---|---|---|---|---|---|
| Baseline: Polyubiquitin Positive Index | 0.99 ± NA | 1.00 ± NA | 0.99 ± NA | — | — | — | — |
| Change at C1D12: Polyubiquitin Positive Index | -0.01 ± NA | 0.00 ± NA | 0.00 ± NA | — | — | — | — |
| Baseline: Ub-histone H2B Positive Index | 0.953 ± NA | 0.995 ± NA | 0.990 ± NA | — | — | — | — |
| Change at C1D12: Ub-histone H2B Positive Index | 0.018 ± NA | 0.003 ± NA | -0.003 ± NA | — | — | — | — |
Best overall response for participant is best observed post-baseline disease response as per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target and non target) must have reduction in short axis to less than (\<) 10 millimeter (mm). Partial Response (PR): at least 30 percent (%) decrease in sum of diameter of target lesions, taking as reference baseline sum of diameter. Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference smallest sum of diameter; PD: at least 20% increase in sum of diameter of target lesions, taking as reference, smallest sum on study (this includes baseline sum if that is smallest on study). In addition to relative increase of 20%, sum must also demonstrate an absolute increase of at least mm. The appearance of 1 or more new lesions is also considered progression.
| percentage of participants | Schedule A: TAK-243 1 mg | Schedule A: TAK-243 2 mg | Schedule A: TAK-243 4 mg | Schedule A: TAK-243 8 mg | Schedule A: TAK-243 12 mg | Schedule A: TAK-243 18 mg | Schedule A: TAK-243 Homozygous Mutant 4 mg |
|---|---|---|---|---|---|---|---|
| CR | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| PR | 33 | 0 | 0 | 0 | 0 | 0 | 0 |
| SD | 67 | 75 | 100 | 0 | 50 | 60 | 0 |
| PD | 0 | 25 | 0 | 100 | 50 | 40 | 100 |
Duration of any response (CR or PR) was defined as the time (in both days and months) from the date of first documented response per the investigator response assessment to the date of first progressive disease after the first documented response or, if the participant discontinues treatment, the date of last disease assessment as per RECIST version 1.1. CR: Disappearance of all target lesions. Any pathological lymph nodes (whether target and non target) must have reduction in short axis to \<10 mm. PR: at least 30% decrease in sum of diameter of target lesions, taking as reference baseline sum of diameter.
| months | Schedule A: TAK-243 1 mg | Schedule A: TAK-243 2 mg | Schedule A: TAK-243 4 mg | Schedule A: TAK-243 8 mg | Schedule A: TAK-243 12 mg | Schedule A: TAK-243 18 mg | Schedule A: TAK-243 Homozygous Mutant 4 mg |
|---|---|---|---|---|---|---|---|
| Duration of Response | 6.24 (6.24 to 6.24) | — | — | — | — | — | — |
Collected over Treatment-emergent adverse events are adverse events that started after the first dose of study drug and no more than 30 days (Cycle 10 Day 41) after the last dose of study drug. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Schedule A: TAK-243 1 mg | — | 1/3 (33.3%) | 3/3 (100%) |
| Schedule A: TAK-243 2 mg | — | 1/4 (25%) | 4/4 (100%) |
| Schedule A: TAK-243 4 mg | — | 2/4 (50%) | 4/4 (100%) |
| Schedule A: TAK-243 8 mg | — | 2/4 (50%) | 4/4 (100%) |
| Schedule A: TAK-243 12 mg | — | 1/5 (20%) | 3/5 (60%) |
| Schedule A: TAK-243 18 mg | — | 4/8 (50%) | 8/8 (100%) |
| Schedule A: TAK-243 Homozygous Mutant 4 mg | — | 0/1 (0%) | 1/1 (100%) |
| Event | Schedule A: TAK-243 1 mg | Schedule A: TAK-243 2 mg | Schedule A: TAK-243 4 mg | Schedule A: TAK-243 8 mg | Schedule A: TAK-243 12 mg | Schedule A: TAK-243 18 mg | Schedule A: TAK-243 Homozygous Mutant 4 mg |
|---|---|---|---|---|---|---|---|
| Escherichia bacteraemiaInfections and infestations | 1/3 | 0/4 | 0/4 | 0/4 | 0/5 | 0/8 | 0/1 |
| PneumoniaInfections and infestations | 0/3 | 0/4 | 0/4 | 1/4 | 1/5 | 0/8 | 0/1 |
| Abdominal painGastrointestinal disorders | 0/3 | 1/4 | 0/4 | 0/4 | 0/5 | 0/8 | 0/1 |
| Breathing abnormalitiesRespiratory, thoracic and mediastinal disorders | 0/3 | 0/4 | 0/4 | 0/4 | 0/5 | 2/8 | 0/1 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/3 | 0/4 | 0/4 | 0/4 | 0/5 | 2/8 | 0/1 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 0/3 | 0/4 | 0/4 | 1/4 | 0/5 | 0/8 | 0/1 |
| Non-small cell lung cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/3 | 0/4 | 0/4 | 1/4 | 0/5 | 0/8 | 0/1 |
| AnaemiaBlood and lymphatic system disorders | 0/3 | 0/4 | 0/4 | 1/4 | 0/5 | 0/8 | 0/1 |
| Acute myocardial infarctionCardiac disorders | 0/3 | 0/4 | 1/4 | 0/4 | 0/5 | 0/8 | 0/1 |
| Infusion related reactionInjury, poisoning and procedural complications | 0/3 | 0/4 | 1/4 | 0/4 | 0/5 | 0/8 | 0/1 |
| Event | Schedule A: TAK-243 1 mg | Schedule A: TAK-243 2 mg | Schedule A: TAK-243 4 mg | Schedule A: TAK-243 8 mg | Schedule A: TAK-243 12 mg | Schedule A: TAK-243 18 mg | Schedule A: TAK-243 Homozygous Mutant 4 mg |
|---|---|---|---|---|---|---|---|
| HyponatraemiaMetabolism and nutrition disorders | 0/3 | 0/4 | 0/4 | 1/4 | 0/5 | 0/8 | 1/1 |
| Neuropathy peripheralNervous system disorders | 0/3 | 0/4 | 0/4 | 0/4 | 0/5 | 0/8 | 1/1 |
| NauseaGastrointestinal disorders | 1/3 | 3/4 | 1/4 | 0/4 | 0/5 | 3/8 | 0/1 |
| AnaemiaBlood and lymphatic system disorders | 0/3 | 1/4 | 1/4 | 1/4 | 0/5 | 4/8 | 0/1 |
| VomitingGastrointestinal disorders | 0/3 | 2/4 | 0/4 | 0/4 | 1/5 | 4/8 | 0/1 |
| Decreased appetiteMetabolism and nutrition disorders | 0/3 | 1/4 | 0/4 | 2/4 | 0/5 | 1/8 | 0/1 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/3 | 2/4 | 2/4 | 1/4 | 0/5 | 2/8 | 0/1 |
| Back painMusculoskeletal and connective tissue disorders | 0/3 | 2/4 | 0/4 | 1/4 | 0/5 | 0/8 | 0/1 |
| FatigueGeneral disorders | 1/3 | 0/4 | 1/4 | 1/4 | 2/5 | 1/8 | 0/1 |
| LeukopeniaBlood and lymphatic system disorders | 1/3 | 0/4 | 0/4 | 0/4 | 0/5 | 1/8 | 0/1 |
The safety population included all participants who received at least 1 dose of TAK-243.
| Age, Continuous(years) | Schedule A: TAK-243 Total |
|---|---|
| Mean | 56.8 ± 9.27 |
| Sex: Female, Male(Participants) | Schedule A: TAK-243 Total |
|---|---|
| Female | 12 |
| Male | 17 |
| Ethnicity (NIH/OMB)(Participants) | Schedule A: TAK-243 Total |
|---|---|
| Hispanic or Latino | 2 |
| Not Hispanic or Latino | 22 |
| Unknown or Not Reported | 5 |
| Race (NIH/OMB)(Participants) | Schedule A: TAK-243 Total |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 5 |
| White | 22 |
| More than one race | 0 |
| Unknown or Not Reported | 2 |
| Region of Enrollment(Participants) | Schedule A: TAK-243 Total |
|---|---|
| United States | 29 |
| Height(centimeter (cm)) | Schedule A: TAK-243 Total |
|---|---|
| Mean | 170.88 ± 12.101 |
| Weight(kilogram (kg)) | Schedule A: TAK-243 Total |
|---|---|
| Mean | 79.69 ± 16.829 |
| Body Surface Area(square meter (m^2)) | Schedule A: TAK-243 Total |
|---|---|
| Mean | 1.936 ± 0.2364 |
Ran from Jan 2014 to primary completion in Nov 2016, 33 months.
Results were first posted in Mar 2019, 2 years 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: TAK-243
Millennium Pharmaceuticals, Inc. →